Tag Archives: Safety pharmacology

New textbook chapter – Modelling Drug Induced Proarrhythmic Risk and a challenge for whole-heart computational modellers

Posted on July 20, 2023 by Gary Mirams

A little note to say that a textbook chapter I wrote last year is now online and available as part of the Springer Reference work “Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays“ The chapter is available here, and if … Continue reading →

Posted in Drug action, Safety Pharmacology, Tissue Simulations, Unexplained | Tagged , , , , , | Leave a comment

2021 CiPA in-silico Modelling Workshop

Posted on June 14, 2021 by Gary Mirams

Abstract submission for the 2021 CiPA in-silico modelling meeting is open now. Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Ion Channel Models, Model Development, Safety Pharmacology | Tagged , , , , , , | Leave a comment

Arrhythmic risk: regression, single cell biophysics, or big tissue simulations?

Posted on March 27, 2017 by Gary Mirams

On the 15th March I presented at an FDA public Advisory Committee hearing on the proposals of the CiPA initative. CiPA aims to replace the current testing for increased drug-induced Torsade de Pointes (TdP) arrhythmic risk, which is a human … Continue reading →

Posted in Action Potential Models, Drug action, Future developments, Model Development, Safety Pharmacology, Tissue Simulations | Tagged , , , , , , , | 3 Comments

Uncertainty quantification for ion channel screening and risk prediction

Posted on November 23, 2016 by Gary Mirams

This post accompanies our new paper in Wellcome Open Research. Regular readers of this blog will know that I worry about uncertainty in the numbers we are using to model drug action on electrophysiology quite a lot – see our … Continue reading →

Posted in Drug action, Model Development, Safety Pharmacology, Stats and Inference | Tagged , , , , , , , , , | 4 Comments

Should I work with IC50s or pIC50s?

Posted on June 13, 2016 by Gary Mirams

When you are expressing how much a drug inhibits something, it’s common to fit a Hill curve through a graph of concentration against % inhibition as shown here: In our case this is often ‘% inhibition’ for a given ionic … Continue reading →

Posted in Drug action, Safety Pharmacology, Stats and Inference | Tagged , , , , , , , , , , , , | 1 Comment

Are 30 compounds enough to test our simulations?

Posted on February 24, 2016 by Gary Mirams

I’ve just contributed to a new review ‘Recent developments in using mechanistic cardiac modelling for drug safety evaluation’, which discusses where we are with using mathematical models of the electrical activity of cardiac muscle cells to predict whether new drugs … Continue reading →

Posted in Action Potential Models, Drug action, Ion Channel Models, Safety Pharmacology, Stats and Inference | Tagged , , , , | 7 Comments

In-silico Action Potential Prediction Web Portal

Posted on July 23, 2014 by Gary Mirams

This post is to announce that we are making our in-silico action potential prediction web portal (AP-predict) available for public use. The portal is free, you just need to register for an account. We’d be happy to have any feedback on … Continue reading →

Posted in Action Potential Models, Drug action, Safety Pharmacology | Tagged , , , , , , , | Leave a comment